BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nigri G, Petrucciani N, Debs T, Mangogna LM, Crovetto A, Moschetta G, Persechino R, Aurello P, Ramacciato G. Treatment options for PNET liver metastases: a systematic review. World J Surg Oncol. 2018;16:142. [PMID: 30007406 DOI: 10.1186/s12957-018-1446-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Lam AK, Ishida H. Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging. Histol Histopathol 2021;36:367-82. [PMID: 33305819 DOI: 10.14670/HH-18-288] [Reference Citation Analysis]
2 Titan AL, Norton JA, Fisher AT, Foster DS, Harris EJ, Worhunsky DJ, Worth PJ, Dua MM, Visser BC, Poultsides GA, Longaker MT, Jensen RT. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors. JAMA Netw Open 2020;3:e2024318. [PMID: 33146734 DOI: 10.1001/jamanetworkopen.2020.24318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ishida H, Lam AK. Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification. Critical Reviews in Oncology/Hematology 2020;145:102835. [DOI: 10.1016/j.critrevonc.2019.102835] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
4 Ayres Pereira M, Chio IIC. Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies. Genes (Basel) 2019;11:E6. [PMID: 31861620 DOI: 10.3390/genes11010006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
5 Dermine S, Palmieri LJ, Lavolé J, Barré A, Dohan A, Abou Ali E, Cottereau AS, Gaujoux S, Brezault C, Chaussade S, Coriat R. Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.J Clin Med. 2019;8. [PMID: 31703375 DOI: 10.3390/jcm8111907] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Doan NV, Duc NM, Ngan VK, Anh NV, Khuyen HK, Nhan NT, Giang BV, Thong PM. Hypovascular pancreatic neuroendocrine tumor with hepatic metastases: A case report and literature review. Radiol Case Rep 2021;16:1424-7. [PMID: 33912257 DOI: 10.1016/j.radcr.2021.03.024] [Reference Citation Analysis]
7 Jiao X, Luan W, Peng X, Liu L, Zhang L, Zhou L. Effects of tumor origins and therapeutic options on the prognosis of hepatic neuroendocrine tumors: A retrospective study. Medicine (Baltimore) 2020;99:e23655. [PMID: 33371100 DOI: 10.1097/MD.0000000000023655] [Reference Citation Analysis]
8 Mastoraki A, Schizas D, Papoutsi E, Ntella V, Kanavidis P, Sioulas A, Tsoli M, Charalampopoulos G, Vailas M, Felekouras E. Clinicopathological Data and Treatment Modalities for Pancreatic Somatostatinomas. In Vivo 2020;34:3573-82. [PMID: 33144470 DOI: 10.21873/invivo.12201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bresciani G, Ditsiou A, Cilibrasi C, Vella V, Rea F, Schiavon M, Cavallesco NG, Giamas G, Zatelli MC, Gagliano T. EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR? Endocr Connect 2019;8:680-90. [PMID: 31035254 DOI: 10.1530/EC-19-0192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Machairas N, Daskalakis K, Felekouras E, Alexandraki KI, Kaltsas G, Sotiropoulos GC. Currently available treatment options for neuroendocrine liver metastases. Ann Gastroenterol 2021;34:130-41. [PMID: 33654350 DOI: 10.20524/aog.2021.0574] [Reference Citation Analysis]
11 Thompson R, Landry CS. Multiple endocrine neoplasia 1: a broad overview. Ther Adv Chronic Dis 2021;12:20406223211035288. [PMID: 34413971 DOI: 10.1177/20406223211035288] [Reference Citation Analysis]
12 Liverani C, Bongiovanni A, Mercatali L, Pieri F, Spadazzi C, Miserocchi G, Di Menna G, Foca F, Ravaioli S, De Vita A, Cocchi C, Rossi G, Recine F, Ibrahim T. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Pathol 2021;32:309-17. [PMID: 33409812 DOI: 10.1007/s12022-020-09657-8] [Reference Citation Analysis]
13 Puckett DL, Alquraishi M, Alani D, Chahed S, Donohoe D, Voy B, Whelan J, Bettaieb A. Zyflamend induces apoptosis in pancreatic cancer cells via modulation of the JNK pathway. Cell Commun Signal 2020;18:126. [PMID: 32795297 DOI: 10.1186/s12964-020-00609-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Wang S, Zhang J, Liu S, Zhang J. The prognostic analysis of different metastatic patterns in pancreatic neuroendocrine tumors patients: A population based analysis. Medicine (Baltimore) 2019;98:e17773. [PMID: 31689842 DOI: 10.1097/MD.0000000000017773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Mpilla GB, Philip PA, El-Rayes B, Azmi AS. Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations. World J Gastroenterol 2020; 26(28): 4036-4054 [PMID: 32821069 DOI: 10.3748/wjg.v26.i28.4036] [Reference Citation Analysis]